Literature DB >> 3954820

Penetration into and elimination from the cerebrospinal fluid of diltiazem, a calcium antagonist, in anesthetized rabbits.

K Naito, T Nagao, M Otsuka, S Harigaya, H Nakajima.   

Abstract

Penetration into and elimination from the cerebrospinal fluid (CSF) of diltiazem were studied following intravenous (i.v.) or intra-cisternal (i.c.) administration of 14C-diltiazem to anesthetized rabbits. 14C-Diltiazem rapidly penetrated into the CSF through the blood-CSF barrier after i.v. injection (1 mg/kg). A CSF level of the radioactivity attained the peak (0.13 microgram eq./ml) 5 min after i.v. injection and declined bi-exponentially with rapid initial half-life of 3.8 min (5-15 min) and second half-life of 2.7 h (15 min-8 h). A CSF/plasma ratio was 0.05-0.2 throughout the observation period. After i.c. administration (100 micrograms/body), the CSF level of the radioactivity decreased with a half-life of 7.5 min up to 1 h. The CSF level was maintained above 10(-7) mol/l until 2-3 h. Elimination half-life of 14C-diltiazem after i.c. injection was much more similar to that of 3H2O than 14C-inulin, indicating that the main elimination route of this compound from the CSF is diffusion into the brain, followed by rapid diffusion into the cerebral capillary, rather than filtration from the sub-arachnoid villi. An autoradiographic investigation supported the above route of elimination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954820

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

2.  Diltiazem Promotes Regenerative Axon Growth.

Authors:  Eric A Huebner; Stéphane Budel; Zhaoxin Jiang; Takao Omura; Tammy Szu-Yu Ho; Lee Barrett; Janie S Merkel; Luis M Pereira; Nick A Andrews; Xingxing Wang; Bhagat Singh; Kush Kapur; Michael Costigan; Stephen M Strittmatter; Clifford J Woolf
Journal:  Mol Neurobiol       Date:  2018-09-19       Impact factor: 5.590

3.  Cromakalim (BRL 34915) counteracts the epileptiform activity elicited by diltiazem and verapamil in rats.

Authors:  P Popoli; A Pezzola; S Sagratella; Y C Zeng; A Scotti de Carolis
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 4.  Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.

Authors:  Fedah E Mohamed; Lihadh Al-Gazali; Fatma Al-Jasmi; Bassam R Ali
Journal:  Front Pharmacol       Date:  2017-07-07       Impact factor: 5.810

5.  In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.

Authors:  Ying Sun; Benjamin Liou; Brian Quinn; Huimin Ran; You-Hai Xu; Gregory A Grabowski
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

6.  Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.

Authors:  Ting-Wei Mu; Douglas M Fowler; Jeffery W Kelly
Journal:  PLoS Biol       Date:  2008-02       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.